Main description:

This Monograph provides an update on cardiovascular disease complications and treatment implications for respiratory diseases, based on current scientific evidence and considered from an epidemiological, pathophysiological and clinical point of view. This book also discusses the future challenges when studying the complex relationship between these two groups of disorders.

Contents:

Epidemiological aspects of cardiovascular and respiratory diseases; Common pathophysiological pathways of the autonomic nervous system; Murine models of cardiovascular damage in lung diseases; Cardiovascular disease in COPD; Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits; Chronic asthma and the risk of cardiovascular disease; Cardiovascular implications in bronchiectasis; Cardiovascular complications of cystic fibrosis; Cardiovascular consequences of sleep disordered breathing: the role of CPAP treatment; The heart in obesity hypoventilation syndrome; Cardiovascular effects of innovative therapies in lung cancer; Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases; Cardiovascular mortality and morbidity in pulmonary embolism; The cardiovascular system in idiopathic pulmonary fibrosis; Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections; Beta2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities; Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists; Impact of inhaled corticosteroids in patients with cardiovascular disease; Cardiovascular side-effects of common antibiotics; The cardiovascular effects of xanthines and selective PDE inhibitors: a risk-benefit analysis; Future challenges; Case reports